The Prognostic Role of Circulating Tumor Cells (CTC) in High-risk Non-muscle-invasive Bladder Cancer
Articolo
Data di Pubblicazione:
2017
Citazione:
The Prognostic Role of Circulating Tumor Cells (CTC) in High-risk Non- muscle-invasive Bladder Cancer / G.M. Busetto, M. Ferro, F. Del Giudice, G. Antonini, B.I. Chung, I. Sperduti, D. Giannarelli, G. Lucarelli, M. Borghesi, G. Musi, O. de Cobelli, E. De Berardinis. - In: CLINICAL GENITOURINARY CANCER. - ISSN 1558-7673. - 15:4(2017), pp. e661-e666. [10.1016/j.clgc.2017.01.011]
Abstract:
Micro-Abstract Circulating tumor cells (CTCs) could represent a promising, noninvasive prognostic and predictive marker in high-risk patients with non-muscle-invasive bladder cancer. We retrospectively evaluated 155 patients with pT1G3 bladder cancer who underwent transurethral resection of bladder tumor after a blood withdrawal for CTC evaluation. In our analysis, the presence of CTCs was significantly associated with time to first recurrence and time to progression. INTRODUCTION:
The purpose of this study was to evaluate the impact of circulating tumor cells (CTCs) as a prognostic marker in patients with high-risk non-muscle-invasive bladder cancer (NMIBC) and assess the efficacy and reliability of 2 different CTC isolation methods.
MATERIALS AND METHODS:
Globally, 155 patients with a pathologically confirmed diagnosis of high-risk NMIBC were included (pT1G3 with or without carcinoma in situ) and underwent transurethral resection of bladder tumor (TURB) after a blood withdrawal for CTC evaluation. A total of 101 patients (Group A) had their samples analyzed with the CellSearch automated system, and 54 (Group B) had their samples analyzed with the CELLection Dynabeads manual system.
RESULTS:
Patients were followed for 28 months, and during this interval, there were a total of 65 (41.9%) recurrences, 27 (17.4%) disease progressions, and 9 (5.8%) lymph node and/or bone metastasis. In our CTC analysis, there were 20 (19.8%) positive patients in Group A and 24 in Group B (44.4%). In our analysis, we found a strong correlation between CTC presence and time to first recurrence; in Group A, we observed an incidence of recurrence in 75% of CTC-positive patients and in Group B of 83% of CTC-positive patients. The time to progression was also strongly correlated with CTCs: 65% and 29%, respectively, of those patients who progressed in those with CTCs in Group A and B.
CONCLUSION:
The study demonstrates the potential role of CTCs as a prognostic marker for risk stratification in patients with NMIBC, to predict both recurrence and progression.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
CELLection; CellSearch; NMIBC; Prognosis; TURB; Oncology; Urology
Elenco autori:
G.M. Busetto, M. Ferro, F. Del Giudice, G. Antonini, B.I. Chung, I. Sperduti, D. Giannarelli, G. Lucarelli, M. Borghesi, G. Musi, O. de Cobelli, E. De Berardinis
Link alla scheda completa: